Literature DB >> 18922919

Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.

Sungyoul Hong1, Jianfei Qian, Jing Yang, Haiyan Li, Larry W Kwak, Qing Yi.   

Abstract

Idiotype (Id) protein, secreted by myeloma cells, is a tumor-specific antigen. Id-based immunotherapy has been explored in patients with myeloma, and results were disappointing. Although previous studies have shown that Id-specific CTLs are able to lyse myeloma cells, it is unclear whether other types of Id-specific T cells, such as type-1 T-helper (Th1) and type-2 T-helper (Th2) cells, are also able to suppress or kill myeloma cells. Using a 5T murine myeloma model, we generated T-cell clones of different subsets and examined their function in the context of myeloma cells. Id-specific CTLs specifically lysed myeloma cells via MHC class I, perforin, and Fas ligand (FasL), and Th1, but not Th2, cells lysed the myeloma cells by FasL-Fas interaction. CTL and Th1 cells also suppressed the growth and function of myeloma cells, whereas Th2 cells promoted the proliferation and enhanced the secretion of Id protein and cytokines by myeloma cells. CTL and Th1, but not Th2, cells were able to eradicate established myeloma in vivo after adoptive transfer. These results show that Id-specific CTL and Th1 are promising effector cells, whereas Th2 provide no protection and may even promote tumor progression in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922919      PMCID: PMC2575640          DOI: 10.1158/0008-5472.CAN-08-2213

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Preparing the ground for vaccination against multiple myeloma.

Authors:  F K Stevenson; K C Anderson
Journal:  Immunol Today       Date:  2000-04

2.  Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes.

Authors:  H Kojima; N Shinohara; S Hanaoka; Y Someya-Shirota; Y Takagaki; H Ohno; T Saito; T Katayama; H Yagita; K Okumura
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

3.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.

Authors:  D Kägi; F Vignaux; B Ledermann; K Bürki; V Depraetere; S Nagata; H Hengartner; P Golstein
Journal:  Science       Date:  1994-07-22       Impact factor: 47.728

4.  Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma.

Authors:  G Cull; L Durrant; C Stainer; A Haynes; N Russell
Journal:  Br J Haematol       Date:  1999-12       Impact factor: 6.998

5.  Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo.

Authors:  F Powrie; S Menon; R L Coffman
Journal:  Eur J Immunol       Date:  1993-11       Impact factor: 5.532

6.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors:  Z Qin; T Blankenstein
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

7.  Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.

Authors:  Siqing Wang; Sungyoul Hong; Michele Wezeman; Jianfei Qian; Jing Yang; Qing Yi
Journal:  Front Biosci       Date:  2007-05-01

8.  Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests.

Authors:  A Osterborg; Q Yi; S Bergenbrant; G Holm; A K Lefvert; H Mellstedt
Journal:  Br J Haematol       Date:  1995-01       Impact factor: 6.998

9.  Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.

Authors:  G F Lauritzsen; S Weiss; Z Dembic; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

10.  Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.

Authors:  S L Topalian; L Rivoltini; M Mancini; J Ng; R J Hartzman; S A Rosenberg
Journal:  Int J Cancer       Date:  1994-07-01       Impact factor: 7.396

View more
  28 in total

1.  Morphine, but not ketamine, decreases the ratio of Th1/Th2 in CD4-positive cells through T-bet and GATA3.

Authors:  Mei Gao; Jie Sun; Wenjie Jin; Yanning Qian
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.

Authors:  Sungyoul Hong; Jianfei Qian; Haiyan Li; Jing Yang; Yong Lu; Yuhuan Zheng; Qing Yi
Journal:  Cancer Immunol Immunother       Date:  2011-10-15       Impact factor: 6.968

Review 3.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

4.  Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.

Authors:  Jianfei Qian; Yuhuan Zheng; Chengyun Zheng; Lijuan Wang; Hong Qin; Sungyoul Hong; Haiyan Li; Yong Lu; Jin He; Jing Yang; Sattva Neelapu; Larry W Kwak; Jian Hou; Qing Yi
Journal:  Blood       Date:  2011-11-02       Impact factor: 22.113

Review 5.  Adoptive T-cell therapy for B-cell malignancies.

Authors:  Michael Hudecek; Larry D Anderson; Tetsuya Nishida; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2009-10       Impact factor: 2.929

6.  MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.

Authors:  Qiang Wang; Dongyu Zhao; Miao Xian; Zhuo Wang; Enguang Bi; Pan Su; Jianfei Qian; Xingzhe Ma; Maojie Yang; Lintao Liu; Youli Zu; Sai Ravi Pingali; Kaifu Chen; Zhen Cai; Qing Yi
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

7.  Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.

Authors:  S Hong; H Li; J Qian; J Yang; Y Lu; Q Yi
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

8.  Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells.

Authors:  Il-Kyu Kim; Byung-Seok Kim; Choong-Hyun Koh; Jae-Won Seok; Jun-Seok Park; Kwang-Soo Shin; Eun-Ah Bae; Ga-Eun Lee; Hyewon Jeon; Jaebeom Cho; Yujin Jung; Daehee Han; Byoung S Kwon; Ho-Young Lee; Yeonseok Chung; Chang-Yuil Kang
Journal:  Nat Med       Date:  2015-08-17       Impact factor: 53.440

9.  Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q.

Authors:  Manish K Aghi; Tracy T Batchelor; David N Louis; Fred G Barker; William T Curry
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

Review 10.  Endotoxin and cancer.

Authors:  Jessica I Lundin; Harvey Checkoway
Journal:  Environ Health Perspect       Date:  2009-05-07       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.